Targeted therapies in the management of metastatic bladder cancer

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 393-406

  Fassan, Matteo ^a   Trabulsi, Edouard J ^a   Gomella, Leonard G ^a   Baffa, Raffaele ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bladder cancer; Gene targeting; Gene therapy; Metastasis; Molecular biology

Indexed keywords

EID: 83455225121     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (189)

1. Aaltonen V, Bostrom PJ, Soderstrom KO, et al. 1999. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. Am J Pathol, 154:755-65.
2. Abraham R, Pagano F, Gomella LG, et al. 2007. Chromosomal deletions in bladder cancer: shutting down pathways. Front Biosci, 12:826-38.
3. Aveyard JS, Skilleter A, Habuchi T, et al. 1999. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer, 80:904-8.
4. Baffa R, Gomella LG, Vecchione A, et al. 2000. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol, 156:419-24.
5. Baffa R, Letko J, McClung C, et al. 2006. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res, 25:145-60.
6. Bagchi S, Weinmann R, Raychaudhuri P. 1991. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell, 65:1063-72.
7. Bajorin DF, McCaffrey JA, Hilton S, et al. 1998. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol, 16:2722-7.
8. Bellmunt J, de Wit R, Albiol S, et al. 2003. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol, 47:195-206.
9. Bellmunt J, Hussain M, Dinney CP. 2003. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol, 46(Suppl):S85-104.
10. Bernardini S, Fauconnet S, Chabannes E, et al. 2001. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol, 166:1275-9.
11. Black PC, Dinney CP. 2007. Bladder cancer angiogenesis and metastasistranslation from murine model to clinical trial. Cancer Metastasis Rev.
12. Bue P, Wester K, Sjostrom A, et al. 1998. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer, 76:189-93.
13. Bykov VJ, Issaeva N, Shilov A, et al. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med, 8:282-8.
14. Bykov VJ, Zache N, Stridh H, et al. 2005. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 24:3484-91.
15. Cairns P, Evron E, Okami K, et al. 1998. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 16:3215-18.
16. Cairns P, Proctor AJ, Knowles MA. 1991. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene, 6:2305-9.
17. Calabro F, Sternberg CN. 2006. State-of-the-art management of metastatic disease at initial presentation or recurrence. World J Urol, 24:543-56.
18. Cappellen D, De Oliveira C, Ricol D, et al. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23:18-20.
19. Carter CA, Chen C, Brink C, et al. 2007. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol, 59:183-95.
20. Chan MW, Chan LW, Tang NL, et al. 2002. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res, 8:464-70.
21. Chellappan SP, Hiebert S, Mudryj M, et al. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell, 65:1053-61.
22. Chow NH, Chan SH, Tzai TS, et al. 2001. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res, 7:1957-62.
23. Chow NH, Liu HS, Lee EI, et al. 1997. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res, 17:1293-6.
24. Christoph F, Schmidt B, Schmitz-Drager BJ, et al. 1999. Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer, 84:169-73.
25. Ciardiello F, Caputo R, Bianco R, et al. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res, 6:2053-63.
26. Ciardiello F, Caputo R, Damiano V, et al. 2003. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res, 9:1546-56.
27. Clifford SC, Thomas DJ, Neal DE, et al. 1994. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br J Cancer, 69:680-6.
28. ClinicalTrials.gov. Information on clinical trials and human research studies. Coombs LM,
29. Pigott DA, Sweeney E, et al. 1991. Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer, 63:601-8.
30. Cordon-Cardo C, Wartinger D, Petrylak D, et al. 1992. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst, 84:1251-6.
31. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. 1997. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res, 57:1217-21.
32. Cote RJ, Datar RH. 2003. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol, 46(Suppl):S67-83.
33. Cote RJ, Esrig D, Groshen S, et al. 1997. p53 and treatment of bladder cancer. Nature, 385:123-5.
34. Cote RJ, Laird PW, Datar RH. 2005. Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol, 23:2879-81.
35. de Bono JS, Rowinsky EK. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med, 8:S19-26.
36. Dei Tos AP. 2007. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers, 22:S3-9.
37. Dimopoulos MA, Moulopoulos LA. 1998. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol, 16:1601-12.
38. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. 2004. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res, 10:4874-84.
39. Dowell SP. 1995. p53 immunocytochemical staining in diagnostic cytopathology: the relevance of the proportion of positive cells. Cytopathology, 6:361-2.
40. Du Z, Hou S. 2003. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol, 170:2000-3.
41. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem, 58:137-71.
42. Esrig D, Elmajian D, Groshen S, et al. 1994. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med, 331:1259-64.
43. Esrig D, Spruck CH 3rd, Nichols PW, et al. 1993. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol, 143:1389-97.
44. Esuvaranathan K, Chiong E, Thamboo TP, et al. 2007. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer, 109:1097-105.
45. Ficarra V, Dalpiaz O, Alrabi N, et al. 2005. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int, 95:786-90.
46. Fitzgerald JM, Ramchurren N, Rieger K, et al. 1995. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst, 87:129-33.
47. Fodor I, Timiryasova T, Denes B, et al. 2005. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol, 173:604-9.
48. Fontana D, Bellina M, Scoffone C, et al. 1996. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol, 29:470-6.
49. Foster BA, Coffey HA, Morin MJ, et al. 1999. Pharmacological rescue of mutant p53 conformation and function. Science, 286:2507-10.
50. Franke KH, Miklosi M, Goebell P, et al. 2000. Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. Urology, 56:689-95.
51. Friend SH, Bernards R, Rogelj S, et al. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 323:643-6.
52. Gallucci M, Guadagni F, Marzano R, et al. 2005. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol, 58:367-71.
53. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. 2002. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer, 95:1009-15.
54. Gardmark T, Wester K, De la Torre M, et al. 2005. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int, 95:982-6.
55. Geller NL, Sternberg CN, Penenberg D, et al. 1991. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer, 67:1525-31.
56. Gomella LG, Mastrangelo MJ, McCue PA, et al. 2001. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol, 166:1291-5.
57. Goodrich DW. 2006. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene, 25:5233-43.
58. Gromova I, Gromov P, Celis JE. 2002. bc10: A novel human bladder cancerassociated protein with a conserved genomic structure downregulated in invasive cancer. Int J Cancer, 98:539-46.
59. Grossman HB, Liebert M, Antelo M, et al. 1998. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res, 4:829-34.
60. Grossman HB, Natale RB, Tangen CM, et al. 2003. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 349:859-66.
61. Habuchi T, Kinoshita H, Yamada H, et al. 1994. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst, 86:1331-5.
62. Hasegawa S, Abe T, Naito S, et al. 1995. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer, 71:907-13.
63. Heise C, Sampson-Johannes A, Williams A, et al. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med, 3:639-45.
64. Hernandez-Alcoceba R, Pihalja M, Wicha MS, et al. 2000. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther, 11:2009-24.
65. Hidalgo M. 2003. Erlotinib: preclinical investigations. Oncology (Williston Park), 17:11-16.
66. Ho CK, Li G. 2005. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br J Dermatol, 153:900-10.
67. Hollstein M, Sidransky D, Vogelstein B, et al. 1991. p53 mutations in human cancers. Science, 253:49-53.
68. Hornigold N, Devlin J, Davies AM, et al. 1999. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene, 18:2657-61.
69. Hussain MH, MacVicar GR, Petrylak DP, et al. 2007. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol, 25:2218-24.
70. Hussain SA, Ganesan R, Hiller L, et al. 2003. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep, 10:571-6.
71. Inoue K, Slaton JW, Perrotte P, et al. 2000. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res, 6:4874-84.
72. Izawa JI, Slaton JW, Kedar D, et al. 2001. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep, 8:9-15.
73. Jain RK, Duda DG, Clark JW, et al. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3:24-40.
74. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
75. Jimenez RE, Hussain M, Bianco FJ Jr, et al. 2001. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res, 7:2440-7.
76. Kamai T, Takagi K, Asami H, et al. 2001. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer, 84:1242-51.
77. Khuri FR, Nemunaitis J, Ganly I, et al. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6:879-85.
78. Kielb SJ, Shah NL, Rubin MA, et al. 2001. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol, 166:482-7.
79. Kikuchi E, Menendez S, Ohori M, et al. 2004. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res, 10:1835-42.
80. Kim ES, Serur A, Huang J, et al. 2002. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA, 99:11399-404.
81. Kinoshita H, Ogawa O, Kakehi Y, et al. 1997. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst, 89:724-30.
82. Knowles MA. 2001. What we could do now: molecular pathology of bladder cancer. Mol Pathol, 54:215-21.
83. Korkolopoulou P, Christodoulou P, Konstantinidou AE, et al. 2000. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol, 31:751-60.
84. Kruger S, Weitsch G, Buttner H, et al. 2002. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer, 102:514-18.
85. Kuball J, Wen SF, Leissner J, et al. 2002. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol, 20:957-65.
86. Kunze E, Von Bonin F, Werner C, et al. 2006. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med, 17:3-13.
87. Kupsch P, Henning BF, Passarge K, et al. 2005. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer, 5:188-96.
88. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, et al. 2002. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett, 186:115-20.
89. Lianes P, Orlow I, Zhang ZF, et al. 1994. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst, 86:1325-30.
90. Lindsey H. 2006. Bevacizumab and erlotinib show promise for kidney cancer. Lancet Oncol, 7:15.
91. Lipponen P, Eskelinen M. 1994. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer, 69:1120-5.
92. Lipponen PK. 1993. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer, 53:365-70.
93. Lo KW, Cheung ST, Leung SF, et al. 1996. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res, 56:2721-5.
94. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. 1992. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 10:1066-73.
95. Logothetis CJ, Xu HJ, Ro JY, et al. 1992. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst, 84:1256-61.
96. Lu ML, Wikman F, Orntoft TF, et al. 2002. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res, 8:171-9.
97. Mahdy E, Pan Y, Wang N, et al. 2001. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Anticancer Res, 21:3167-73.
98. McGarvey TW, Maruta Y, Tomaszewski JE, et al. 1998. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene, 17:1167-72.
99. McKnight JJ, Gray SB, O'Kane HF, et al. 2005. Apoptosis and chemotherapy for bladder cancer. J Urol, 173:683-90.
100. Mellon JK, Lunec J, Wright C, et al. 1996. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol, 155:321-6.
101. Mellon K, Wright C, Kelly P, et al. 1995. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol, 153:919-25.
102. Mendelsohn J. 2000. Blockade of receptors for growth factors: an anticancer therapy the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res, 6:747-53.
103. Mendelsohn J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol, 20:1S-13S.
104. Mendelsohn J, Dinney CP. 2001. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol, 165:1152-7.
105. Messing EM. 1990. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res, 50:2530-7.
106. Messing EM. 1992. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol, 8:285-92.
107. Meyerhardt JA, Zhu AX, Enzinger PC, et al. 2006. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol, 24:1892-7.
108. Migaldi M, Sgambato A, Garagnani L, et al. 2000. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res, 6:3131-8.
109. Mitra AP, Datar RH, Cote RJ. 2006. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol, 24:5552-64.
110. Moriyama M, Akiyama T, Yamamoto T, et al. 1991. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol, 145:423-7.
111. Naito S, Sakamoto N, Kotoh S, et al. 1992. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur Urol, 22:158-62.
112. Neal DE, Mellon K. 1992. Epidermal growth factor receptor and bladder cancer: a review. Urol Int, 48:365-71.
113. Neal DE, Sharples L, Smith K, et al. 1990. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65:1619-25.
114. Nguyen PL, Swanson PE, Jaszcz W, et al. 1994. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol, 101:166-76.
115. Nicholson RI, Gee JM, Harper ME. 2001. EGFR and cancer prognosis. Eur J Cancer, 37(Suppl 4):S9-15.
116. Nixdorf S, Grimm MO, Loberg R, et al. 2004. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett, 215:209-20.
117. Nutt JE, Lazarowicz HP, Mellon JK, et al. 2004. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer, 90:1679-85.
118. Nutt JE, Mellon JK, Qureshi K, et al. 1998. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer, 78:215-20.
119. Oliner JD, Kinzler KW, Meltzer PS, et al. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358:80-3.
120. Orlow I, LaRue H, Osman I, et al. 1999. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol, 155:105-13.
121. Pagano F, Bassi P, Galetti TP, et al. 1991. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol, 145:45-50.
122. Pagliaro LC, Keyhani A, Liu B, et al. 2003. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol, 21:456-62.
123. Pagliaro LC, Keyhani A, Williams D, et al. 2003. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol, 21:2247-53.
124. Panka DJ, Wang W, Atkins MB, et al. 2006. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res, 66:1611-19.
125. Parimoo D, Raghavan D. 2000. Progress in the management of metastatic bladder cancer. Cancer Control, 7:347-56.
126. Perrotte P, Matsumoto T, Inoue K, et al. 1999. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res, 5:257-65.
127. Petrylak DP, Scher HI, Reuter V, et al. 1994. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol, 5:835-40.
128. Pfister C, Buzelin F, Casse C, et al. 1998. Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression. Eur Urol, 33:278-84.
129. Pfister C, Flaman JM, Dunet F, et al. 1999. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol, 162:69-73.
130. Pfister C, Moore L, Allard P, et al. 1999. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res, 5:4079-84.
131. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. 2004. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol, 22:93-101.
132. Proctor AJ, Coombs LM, Cairns JP, et al. 1991. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene, 6:789-95.
133. Raghavan D, Shipley WU, Garnick MB, et al. 1990. Biology and management of bladder cancer. N Engl J Med, 322:1129-38.
134. Ravery V, Grignon D, Angulo J, et al. 1997. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res, 25:9-17.
135. Redman BG, Smith DC, Flaherty L, et al. 1998. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol, 16:1844-8.
136. Ries S, Korn WM. 2002. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer, 86:5-11.
137. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291-310.
138. Roth BJ, Dreicer R, Einhorn LH, et al. 1994. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 12:2264-70.
139. Rotterud R, Fossa SD, Nesland JM. 2007. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol, 22:349-63.
140. Sardi I, Dal Canto M, Bartoletti R, et al. 1998. Molecular genetic alterations of c-myc oncogene in superficial and locally advanced bladder cancer. Eur Urol, 33:424-30.
141. Sarkis AS, Bajorin DF, Reuter VE, et al. 1995. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol, 13:1384-90.
142. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. 1993. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst, 85:53-9.
143. Sato K, Moriyama M, Mori S, et al. 1992. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70:2493-8.
144. Sawyers CL. 2002. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev, 12:111-15.
145. Schmitz-Drager BJ, Kushima M, Goebell P, et al. 1997. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol, 32:487-93.
146. Scholl S, Beuzeboc P, Pouillart P. 2001. Targeting HER2 in other tumor types. Ann Oncol, 12(Suppl 1):S81-7.
147. Sen S, Zhou H, Zhang RD, et al. 2002. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst, 94:1320-9.
148. Senderowicz AM. 2003a. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther, 2:S84-95.
149. Senderowicz AM. 2003b. Small-molecule cyclin-dependent kinase modulators. Oncogene, 22:6609-20.
150. Sgambato A, Migaldi M, Faraglia B, et al. 1999. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res, 59:3245-50.
151. Shariat SF, Kim J, Raptidis G, et al. 2003. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology, 61:1140-5.
152. Shariat SF, Tokunaga H, Zhou J, et al. 2004. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol, 22:1014-24.
153. Shiina H, Igawa M, Nagami H, et al. 1996. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer, 78:1762-74.
154. Shiina H, Igawa M, Shigeno K, et al. 1999. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology, 56:239-47.
155. Shin KY, Kong G, Kim WS, et al. 1997. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer, 75:1788-92.
156. Sibley K, Cuthbert-Heavens D, Knowles MA. 2001. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene, 20:686-91.
157. Sidransky D, Von Eschenbach A, Tsai YC, et al. 1991. Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252:706-9.
158. Silay MS, Miroglu C. 2007. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Med Hypotheses.
159. Siu LL, Awada A, Takimoto CH, et al. 2006. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res, 12:144-51.
160. Skopelitou AS, Gloustianou G, Bai M, et al. 2001. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo, 15:169-73.
161. Slichenmyer WJ, Fry DW. 2001. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol, 28:67-79.
162. Small EJ, Halabi S, Dalbagni G, et al. 2003. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer, 97:2090-8.
163. Soini Y, Turpeenniemi-Hujanen T, Kamel D, et al. 1993. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer, 68:1029-35.
164. Sriplakich S, Jahnson S, Karlsson MG. 1999. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int, 83:498-503.
165. Stein JP, Ginsberg DA, Grossfeld GD, et al. 1998. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst, 90:1072-9.
166. Stein JP, Grossfeld GD, Ginsberg DA, et al. 1998. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol, 160:645-59.
167. Sternberg CN, Yagoda A, Scher HI, et al. 1989. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer, 64:2448-58.
168. Tanner S, Barberis A. 2004. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed, 3:5.
169. Uchida T, Minei S, Gao JP, et al. 2002. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep, 9:253-9.
170. Uchida T, Wada C, Ishida H, et al. 1995. Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int, 55:63-7.
171. Underwood M, Bartlett J, Reeves J, et al. 1995. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res, 55:2422-30.
172. Vale C. 2005. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 48:202-5; discussion 205-6.
173. Vaughn DJ, Malkowicz SB, Zoltick B, et al. 1998. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol, 16:255-60.
174. Vecchione A, Ishii H, Baldassarre G, et al. 2002. FEZ1/LZTS1 is downregulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol, 160:1345-52.
175. Vecchione A, Sevignani C, Giarnieri E, et al. 2004. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res, 10:7607-12.
176. Vollmer RT, Humphrey PA, Swanson PE, et al. 1998. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer, 82:715-23.
177. von der Maase H, Hansen SW, Roberts JT, et al. 2000. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18:3068-77.
178. Wang DS, Rieger-Christ K, Latini JM, et al. 2000. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer, 88:620-5.
179. Watters AD, Latif Z, Forsyth A, et al. 2002. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer, 87:654-8.
180. Wester K, Sjostrom A, de la Torre M, et al. 2002. HER-2 a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol, 41:282-8.
181. Wick MR. 1988. Paul Ehrlich: the prototypic clinical pathologist. Am J Clin Pathol, 90:329-32.
182. Wu X, Bayle JH, Olson D, et al. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev, 7:1126-32.
183. Wu XR. 2005. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer, 5:713-25.
184. Xu HJ, Cairns P, Hu SX, et al. 1993. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer, 53:781-4.
185. Xu HJ, Xu K, Zhou Y, et al. 1994. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci USA, 91:9837-41.
186. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 5:37-50.
187. Zavrski I, Jakob C, Schmid P, et al. 2005. Proteasome: an emerging target for cancer therapy. Anticancer Drugs, 16:475-81.
188. Zhang X, Multani AS, Zhou JH, et al. 2003. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res, 63:760-5.
189. Zu X, Tang Z, Li Y, et al. 2006. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int, 98:1090-3.